Company intelligence / Profile preview

NuBiyota

Ownership: Private
Development stage: Phase 2

Overview

NuBiyota is developing microbiome-based therapeutics with its most advanced candidate (MET-4) in Phase 2/3 for advanced malignant solid neoplasm. Other candidates include MET-2 (Phase 2 for anxiety disorders) and MET-3 (Phase 2 for hypertriglyceridemia).

Therapeutic areas: GastroenterologyPsychiatryMetabolic DisordersOncologyInfectious Diseases
Modalities: Live biotherapeutic productsMicrobial Ecosystem Therapeutic products
Industry: Biotech

Drug pipeline

3 assets

MET-3

2 more assets in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceutical Company

Beyond the preview

Go deeper on NuBiyota.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuBiyota.

Explore the full profile